Mental Disorders

It is hard to read the news these days without hearing that many people in need of mental-health care aren’t getting it. Consideration of suicide shot up during the pandemic; opioid deaths soared 30%; the Surgeon General has warned of a…

Cerebral Inc., the online mental-health company, said on Saturday it has been subpoenaed by federal prosecutors as part of an investigation into possible violations of the Controlled Substances Act.…

Cerebral executives told its clinicians that the company will pause prescribing controlled substances like Adderall to treat attention deficit hyperactivity disorder in new patients beginning Monday, the company said.…

Biogen Inc. Chief Executive Michel Vounatsos will resign from the company as it slims down its workforce and cuts spending by $1 billion annually, and attempts to chart a new…

Cat Contillo remembers how uncomfortable she felt during an office internship a few years ago because of colleagues’ reactions to her masculine outfits and her inability to understand sarcasm.Ms. Contillo,…

To woo consumers, hotel chains typically offer free room upgrades and complimentary breakfast. Kimpton Hotels is trying a new incentive: help with mental health.In a recent social-media campaign, the boutique-hotel operator said it is…

Cris Wibby joined online mental-health company Cerebral Inc. as a nurse practitioner last spring, looking for the flexibility to work from home while helping new patients.She began treating adults with attention deficit hyperactivity…

To a neuroscientist like me, the inner workings of our emotional brains seem as mysterious as the inner workings of a black hole must have seemed to an astrophysicist like my late father. Yet everyone seems to think they understand emotions…

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the…

Biogen Inc. BIIB 0.81% is slashing in half the price of its controversial new Alzheimer’s disease treatment, Aduhelm, in a bid to revive a product launch that has…